Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 1, 2007, Pages 78-83

  Levy Neumand, Olivier ^a,c   Carniaux, François ^b   Bonaz, Bruno ^b   Durand, Aurélie ^b   Roblin, Xavier ^b  

^a Service du Contrôle Médical de l'Assurance Maladie   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c Échelon Local du Service Médical de Grenoble   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG MARKETING; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; QUESTIONNAIRE; TIME SERIES ANALYSIS;

EID: 33846839346     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89330-4     Document Type: Article

References (19)

1. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998;317:452-6.
2. Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42 Suppl 3:iii23-iii31.
3. Agence Française de Sécurité Sanitaire des Produits de Santé. Recommandations de bonnes pratiques ; les anti-ulcéreux : indications chez l'adulte. Paris : AFSSAPS;1999. http://afssaps.sante.fr.
4. VIDAL. Dictionnaire VIDAL.Issy-les-Moulineaux .2004.
5. Thiefin G.C complications gastro-intestinales des anti-inflammatoires non stéroïdiens et de l'aspirine à faible dose. Gastroenterol Clin Biol 2003;27:498-510.
6. Conférence de consensus. Société nationale française de gastro-entérologie. Reflux gastro-oesophagien de l'adulte: "diagnostic et traitement". Tours: SNFG;1999. Gastroenterol Clin Bio 1999;23:no 1bis.
7. Agence nationale d'accréditation et d'évaluation en santé. Indications à visée diagnostique de l'endoscopie digestive haute en pathologie gastro-duodénale. Paris:ANAES;2001. http://www.has-sante.fr.
8. Clinard F, Sgro C, Bardou M, Dumas M, Hillon P, Bonithon-Kopp C. Non-steroidal anti-inflammatory drug prescribing patterns in general practice: comparison of a general practitioner-based survey and a pharmacy-based survey in France. Pharmacoepidemiol Drug Saf 2001;10:329-38.
9. Barthelme I. Prescrire hors AMM, les raisons, les risques. Concours Med. 2005;127(06):349-52.
10. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
11. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-32.
12. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
13. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
14. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
15. Bytzer P.Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98:S31-S39.
16. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-40.
17. Talley NJ, Moore MG, Sprogis A, Katelaris P. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust 2002;177:423-7.
18. Maton PN, Orlando R, Joelsson B. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial. Aliment Pharmacol Ther 1999;13:819-26.
19. Jian R, Hassani Z, El Kebir S, Barthelemy P. Management of gastro-oesophageal reflux disease in primary care. Results from an observational study of 2 474 patients. Gastroenterol Clin Biol 2007;31:72-7.